多囊肾小鼠模型孕期和哺乳期的线粒体药物治疗：对母亲及其后代来说都是双赢。

Mitochondrial pharmacotherapy during pregnancy and lactation in an ADPKD mouse model: a win for both mothers and their offspring.

作者信息

Wang Wei, Tran Pamela V

机构信息

Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, USA; The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA.

出版信息

Kidney Int. 2022 May;101(5):870-872. doi: 10.1016/j.kint.2022.02.008.

DOI:10.1016/j.kint.2022.02.008

PMID:35461611

Abstract

Pharmacotherapies that are safe during pregnancy are lacking for patients with autosomal dominant polycystic kidney disease. In this issue, Daneshgar et al. reveal that administration of the mitochondrial-protective peptide, elamipretide, during pregnancy and lactation in a mouse model with autosomal dominant polycystic kidney disease, is nonteratogenic and attenuates disease severity in both mothers and their affected offspring. This finding suggests therapeutic potential of elamipretide during pregnancy, in utero, and in early postnatal life.

摘要

对于患有常染色体显性多囊肾病的患者而言，孕期安全的药物治疗方法尚不存在。在本期杂志中，达内什加尔等人揭示，在患有常染色体显性多囊肾病的小鼠模型中，孕期和哺乳期给予线粒体保护肽艾拉米肽，不会产生致畸作用，并且会减轻母亲及其患病后代的疾病严重程度。这一发现表明艾拉米肽在孕期、子宫内及出生后早期具有治疗潜力。